A new AI foundation model from Mass General Brigham may be capable of analyzing brain MRI datasets and predict various ...
Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical stage biopharmaceutical company developing cell therapies for patients with autoimmune diseases ...
Everyday Health on MSN
Beyond the CIDP infusion: Why physical therapy is your secret weapon for remission
Medication stops the attack, but physical therapy rebuilds the strength. Learn how specialized neuro-PT helps ‘re-map’ movements and prevent permanent damage in chronic inflammatory demyelinating ...
The Work at Home Woman on MSN
17 flexible work from home jobs for people with a chronic illness
Are you struggling to keep a job and earn an income due to your chronic condition? Here are some of the best work at home ...
A collaborative team of researchers and students from Wayne State University's Eugene Applebaum College of Pharmacy and ...
Biogen Inc. (BIIB) reported $2.28 billion in revenue for the quarter ended December 2025, representing a year-over-year decline of 7.1%. EPS of $1.99 for the same period compares to $3.44 a year ago.
Meeting with the FDA to review the results from the Phase 3 EFZO-FIT™ study and determine the path forward for efzofitimod in ...
Medical marijuana could soon be reclassified into a medical category that includes prescription drugs like Tylenol with ...
EMERYVILLE, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical stage biopharmaceutical company developing cell therapies for patients with autoimmune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results